Ronak Savla holds a PharmD and PhD in Pharmaceutical Sciences from Rutgers University and an MBA from Johns Hopkins University – Carey Business School. Prior to joining as a Blavatnik fellow, Ronak was the Senior Director of Strategic Ventures at Catalent Pharma Solutions, where he managed the company’s strategic limited partnerships, and worked closely with leading life science investment firms, biotech incubators, universities, and other organizations that support early-stage biotech companies. Ronak led several corporate initiatives that enhanced Catalent’s approach and offerings for early-stage biotech companies. Previously, he led Medical Affairs and New Product Planning at Innate Pharma, supporting the commercial launch of a novel rare leukemia therapy and multiple clinical stage assets. He has spent his career at the intersection of science, capital, and execution.